Siolta Therapeutics Enters into a Joint Research Agreement with Cowellnex
Shots:
- Siolta Therapeutics has entered into a preclinical research partnership with Cowellnex, a joint investment of Kirin and Kyowa Kirin, to develop an LBP focused on preventing necrotizing enterocolitis (NEC)
- The collaboration will utilize Siolta’s Precision Symbiotics Platform, enabling Cowellnex to expedite the discovery and development of innovative product aimed at preventing the occurrence of NEC
- Precision Symbiotics Platform helps in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies for developing innovative products
Ref: Businesswire | Image: Siolta Therapeutics
Related News:- Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
